Quest Diagnostics Incorporated (DGX) Stock
DGX Key Statistics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
CEO: James E. Davis. Company website
DGX — Frequently Asked Questions
What is the DGX stock price today?
Quest Diagnostics Incorporated (DGX) trades at $246.48, down 0.39% on the day, as of Sep 20, 2026 13:47 UTC.
What is Quest Diagnostics Incorporated's market cap?
Quest Diagnostics Incorporated has a market capitalisation of $27.20B, calculated from the live DGX share price and shares outstanding.
What is the P/E ratio of DGX?
DGX trades at a trailing P/E of 26.17, from earnings per share of $9.42 over the last twelve months.
How much revenue does Quest Diagnostics Incorporated make?
Quest Diagnostics Incorporated generated revenue of $11.56B over the trailing twelve months, which puts the stock at 2.35 times sales.
Does DGX pay a dividend?
Yes. Quest Diagnostics Incorporated pays a dividend yielding 1.71% on the current share price.
What is the 52-week range for DGX?
DGX has traded between $171.18 and $248.70 over the past 52 weeks, and the last price is 0.9% below that high.
Is Quest Diagnostics Incorporated profitable?
Yes. Quest Diagnostics Incorporated keeps 9.19% of revenue as net income over the trailing twelve months.
What is the analyst price target for DGX?
Wall Street analysts rate DGX Hold, with an average price target of $246.67, 0.1% above the current price.
What sector is Quest Diagnostics Incorporated in?
Quest Diagnostics Incorporated is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Quest Diagnostics Incorporated?
James E. Davis is the chief executive of Quest Diagnostics Incorporated, which employs 51,500 people.
Where can I track DGX in real time?
QFI Terminal shows DGX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See DGX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open DGX in Terminal See plans